FDA Current Trends in Compliance and Enforcement for FDA-Regulated Computer Systems and Data
As the pace of technological innovation and evolution becomes more intense, there is a critical need for computer system validation, 21 CFR Part 11 (Electronic Records and Electronic Signatures) compliance, and data integrity assurance to continue in environme
Speaker
Carolyn Troiano
Overview
FDA became alarmed by the lack of compliance to meet data integrity and Part 11 requirements during the last decade. Out of compliance citations during this period, including Form 483s and Warning Letters have skyrocketed. But why?
Based on discussions with clients and stakeholders at conferences and meetings, it has become more and more obvious that most of the performers in industry are under management pressure to do more work with fewer resources and in less time. This continues to lead performers to seek faster and easier ways to get the work done, causing them to rush through their work, resulting in unforced errors, and leading some to even take shortcuts that could lead to findings of fraud. Being optimistic about this, it also opens the door for more serious conversation around the use of AI and other technologies in software development, testing, and support. This is compounded further by the greater efficiencies promised by following CSA and removing work that does not add value while assuring risk is appropriately assessed and mitigated.
As we find ourselves in the midst of technology and compliance revolutions, It is time to prepare ourselves and be ready to leverage them to deliver quality products that meet the needs of consumers. Providing consumers with newer, safer, and more innovative and effective products is key to both FDA’s and industry’s focus on public safety.
Why attend: Providing safe and effective medical devices, drugs, and other FDA-regulated products is in the best interests of all those involved in the development, manufacturing, testing, and distribution of these products. Current industry drivers, including the rising demand for healthcare, expansion of specialty medicines & physician shortages require key strategies to alleviate pressures & accelerate the delivery of safe & effective products to the marketplace. As demand surges & complexity of cases requires approaches leveraging the latest medical knowledge, rapid access to accurate information is essential to quality. Only by leveraging the latest in innovative technology will the industry catch up to where delivery is meeting demand. Along with companies, FDA has begun pilot programs using these technologies and is working to develop the appropriate regulatory framework to ensure products are safe & effective. Several discussion papers have been issued over the last few years & updated based on stakeholder feedback. Ultimately, these will be key elements for driving success. We will compare traditional Computer System Validation (CSV) with Computer Software Assurance (CSA), the latter of which is the subject of FDA’s September 2022 draft guidance for industry. We will talk about the changes in the newer GAMP®5, 2nd Edition & how these align with CSA. While CSA remains a draft guidance, it will likely be finalized in the near future & companies must be prepared. In addition to technology, we will discuss a variety of current trends in FDA compliance & enforcement. Over the last decade, we have seen an increase in citations related to 21 CFR Part 11 (electronic records/signatures) & data integrity (ALCOA+ principles) deficiencies. Laboratory areas have been the subject of many FDA findings, particularly around audit trail management & use, risk assessment, access controls & security.
What’s covered
- Artificial Intelligence (AI)
- Machine Learning (ML)
- Large Language Models (LLMs), such as ChatGPT
- FDA Compliance for Computer System Validation
- Traditional Computer System Validation (CSV)
- Computer Software Assurance (CSA)
- System Development Life Cycle (SDLC) Methodology
- GAMP®5, 2nd Edition
- GAMP®5 Software Categories
- 21 CFR Part 11, FDA Guidance for Using Electronic Records/Electronic Signatures in Regulated Computer Systems
- Data Integrity Compliance
- Critical Thinking
- Risk Assessment
- Risk-Based Approach to Validation
- Commercial-Off-the-Shelf (COTS) Software
- Software-as-a-Service (SaaS) Solutions
- Cloud Services
- Automated Testing
- Systems and Organizational Control (SOC) Certification
- Vendor Audit
- Periodic System Review
- FDA Compliance Trends
- Current Industry Best Practices
- Q&A.
Who should attend
What you get
About the speaker
Carolyn Troiano has more than 35 years of experience in the tobacco, pharmaceutical, medical device and other FDA-regulated industries. She has worked directly, or on a consulting basis, for many of the larger pharmaceutical and tobacco companies in the US and Europe, developing and executing compliance strategies and programs. Carolyn is currently active in the Association of Information Technology Professionals (AITP), and Project Management Institute (PMI) chapters in the Richmond, VA area.
During her career, Carolyn worked directly, or on a consulting basis, for many of the larger pharmaceutical companies in the US and Europe. She developed validation programs and strategies back in the mid-1980s, when the first FDA guidebook was published on the subject, and collaborated with FDA and other industry representatives on 21 CFR Part 11, the FDA’s electronic record/electronic signature regulation.

